| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:18779953 | IVR | 300 mg/kg | - | No significant effects observed | - |
| IVR | 125 mg/kg | 125 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increased weights of seminal vesicles | Reproductive endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Affects liver function | Hepatic endocrine-mediated perturbations | |
| IVR | 125 mg/kg | 125 mg/kg | Decreased spleen weights | Immunological endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg | 25 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1000 mg/kg | - | No significant effects observed | - | |
| IVR | 5 mg/kg | - | No significant effects observed | - | |
| IVR | 200 mg/kg | - | No significant effects observed | - | |
| IVR | 100 mg/kg | - | No significant effects observed | - | |
| IVR | 40 mg/kg | - | No significant effects observed | - | |
| IVR | 25 mg/kg | 25 mg/kg | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:33892370 | IVR | 25 mg/kg/day | 25 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 5 - 25 mg/kg/day | 5 - 25 mg/kg/day | Decreased body weights in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg/day | 5 - 25 mg/kg/day | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg/day | 5 - 25 mg/kg/day | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 25 mg/kg/day | 25 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:34757178 | IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Decrease in T4 levels | Metabolic endocrine-mediated perturbations |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Decreased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Decreased body weights in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Affects thyroid hormone metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Changes in morphology of thyroid gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Increased weights of thyroid gland in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Increase in TSH levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Decrease in T3 levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Decrease in T4 levels in offspring | Developmental endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg | 5 - 25 mg/kg | Decrease in TSH levels | Metabolic endocrine-mediated perturbations | |
| PMID:35385133 | IVR | 1 ppm | 1 ppm | Decreased triglycerides level | Metabolic endocrine-mediated perturbations |
| IVR | 1 ppm | 1 ppm | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decrease in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decrease in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Hypertrophy in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Hyperplasia in thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Changes in morphology of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 1 ppm | 1 ppm | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| PMID:38685447 | IVR | 5 mg/kg/day | 5 mg/kg/day | Affects brain development | Developmental endocrine-mediated perturbations;Neurological endocrine-mediated perturbations |
| PMID:39134236 | IVR | 5 mg/kg/day | 5 mg/kg/day | Decrease in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects thyroid hormone signaling | Metabolic endocrine-mediated perturbations | |
| PMID:39414071 | IVR | 5 mg/kg/day | 5 mg/kg/day | Increased progesterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 5 - 25 mg/kg/day | 5 - 25 mg/kg/day | Decreased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects anogenital distance | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 - 25 mg/kg/day | 5 - 25 mg/kg/day | Changes in morphology of seminiferous tubules | Reproductive endocrine-mediated perturbations | |
| PMID:4177895 | IVR | 0.25 mg/L | - | No significant effects observed | - |
| IVR | 2 mg/L | 2 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/L | 2 mg/L | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/L | 0.5 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 0.5 mg/L | 0.5 mg/L | Affects iodine uptake into thyroid | Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/L | 10 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 50 mg/L | 50 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| PMID:6868082 | IVR | 100 mg/L | 100 mg/L | Pituitary gland carcinoma | Endocrine-mediated cancer;Neurological endocrine-mediated perturbations |
| IVR | 1 mg/L | - | No significant effects observed | - | |
| IVR | 100 mg/L | 100 mg/L | Thyroid gland carcinoma | Endocrine-mediated cancer;Metabolic endocrine-mediated perturbations | |
| IVR | 10 mg/L | - | No significant effects observed | - | |
| IVR | 100 mg/L | 100 mg/L | Affects survival of live fetus | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Affects thyroid function | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/L | 100 mg/L | Changes in morphology of pituitary gland | Neurological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.